significant announcements made by ACR since 22/06/22 Jublia...

significant announcements made by ACR since

22/06/22 Jublia Generic Approved
28/07/21 Elma Generic Approved
26/08/21 Testerone Generic Launched
13/09/21 5th dossier for Dapsone Gel 5% submitted to FDA
30/05/22 Successful Patent Ligation outcome for Dapsone Gel 7.5%
8/08/22 6th dossier for Acyclovir Cream 5% submitted to FDA
21/12/22 Elma Generic Launched



18 months of positive announcements that have had no effect on the share price.
Positive announcements can be dismissed by the market for only so long.

I also see the 15/12/22 announcement of ACR and Amring parting ways as positive. As (1) the development of this generic is still happening with a dossier expected to be submitted late 2023 and (2)hopefully the handling of this dossier will pass to Padagis.

of course there have been announcements that have not come to pass.. the big one being cashflow positive by end of year 2022.

But (IMO) it's coming. Jet